NasdaqGS:ORICBiotechs
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3
ORIC Pharmaceuticals recently reported detailed Phase 1b dose-optimization data for rinzimetostat in metastatic castration-resistant prostate cancer and, based on an 84% 5‑month radiographic progression-free survival and favorable tolerability at 400 mg once daily with darolutamide, selected this regimen as the recommended Phase 3 dose for the planned global Himalayas-1 registrational trial starting in the first half of 2026.
Beyond the headline efficacy, the company’s extensive...